ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 405

Gout and RA: Not Such a Rare Coexistence After All

Christina Petsch1, Elizabeth Araujo1, Matthias Englbrecht1, Axel J. Hueber2, Georg Schett1, Bernhard Manger1 and Juergen Rech2, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: gout, rheumatoid arthritis (RA) and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

According to the current rheumatology literature, the simultaneous occurrence of rheumatoid arthritis (RA) and gout is rare and only a few cases have been reported to date (1). However, clinical practice suggests otherwise. The goal of this study was to investigate the coexistence of RA and gout in patients with known RA and identify prognostic factors that could lead to the development of gout in these patients.

Methods:

Patients who fulfilled ACR criteria for RA and had a serum uric acid (SUA) level above 6 mg/dl were included. The presence of uric acid deposits in joints was confirmed by means of a dual energy computed tomography (DECT). DECT is a new imaging tool which uses x-ray beams of two different energies to differentiate monosodium urate (MSU) deposits from connective tissues and from calcium containing structures by their absorption properties (2). The following baseline parameters were assessed: gender, age, BMI, duration of disease, DAS 28, current RA therapy, use of medications that interfere with SUA, ESR, CRP, SUA  and presence of metabolic syndrome. DECT of patients’ feet was performed.

Results:

100 patients (45 females, 55 males) were recruited. 55 patients were seropositive and 45 seronegative. Mean ± SD age was 63.05 ±11.15 years, mean ± SD duration of disease was 8.76 ± 11.15 years, mean ± SD DAS 28 was 3,28 ±1,58. DECT was positive in 16.3% of all scanned patients (9% in seropositive and 24% in seronegative patients). Regarding those, the mean ± SD SUA level was 7,82 ±2,18 mg/dl, mean ± SD age was 63.44 ± 11.71 years, and mean ±SD BMI was 28.06 ±3.45. 88% were male, 20% had a metabolic syndrome and 69% were taking medications that could elevate SUA. According to a logistic regression model analysis, the following parameters showed significance for the presence of uric acid deposits: male gender (Wald x² = 3.897, Exp B =5.678, 95% CI= 1.013 – 31.844, p=0.048) and seronegativity (Wald x²= 4.973, Exp B = 0.171, 95% CI= 0.036 – 0.807, p=0.026). Interestingly, SUA was not statistically significant.

Conclusion:

Our study showed that a considerable number of patients with a diagnosis of RA and elevated SUA level present MSU deposits in typical locations. Male gender and seronegative status are independent variables related to positive findings. Based on this study it is always necessary to think of gout as an additional diagnosis in patients with RA and hyperuricemia.

References:

  1. Kuo CF, Tsai WP, Liou LB. Rare copresent rheumatoid arthritis and gout: comparison with pure rheumatoid arthritis and a literature review. Clin Rheumatol. 2008 Feb; 27(2):231-5.
  2. Manger B, Lell M, Wacker J, Schett G, Rech J. Detection of periarticular urate deposits with dual energy CT in patients with acute gouty arthritis. Ann Rheum Dis. 2012 Mar;71(3):470-2.

Disclosure:

C. Petsch,
None;

E. Araujo,
None;

M. Englbrecht,
None;

A. J. Hueber,
None;

G. Schett,
None;

B. Manger,
None;

J. Rech,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gout-and-ra-not-such-a-rare-coexistence-after-all/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology